Related references
Note: Only part of the references are listed.Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas
Laura H. Tang et al.
CLINICAL CANCER RESEARCH (2016)
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
Laura H. Tang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
R. Garcia-Carbonero et al.
NEUROENDOCRINOLOGY (2016)
Small Cell Carcinomas of the Bladder Highly Express Somatostatin Receptor Type 2A: Impact on Prognosis and Treatment-A Multicenter Study of Urooncology Society, Turkey
Nalan Nese et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role
George Kanakis et al.
NEUROENDOCRINOLOGY (2015)
Pathology, genetics and precursors of human and experimental pancreatic neoplasms: An update
Irene Esposito et al.
PANCREATOLOGY (2015)
Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms
Daniel Kaemmerer et al.
ONCOTARGET (2015)
Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies
Michelle D. Reid et al.
MODERN PATHOLOGY (2015)
Gastroenteropancreatic High-Grade Neuroendocrine Carcinoma
Halfdan Sorbye et al.
CANCER (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Pancreatic neuroendocrine tumors: Pathologic and molecular characteristics
Chanjuan Shi et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Fritz-Line Velayoudom-Cephise et al.
ENDOCRINE-RELATED CANCER (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry
Gou Mizutani et al.
ACTA HISTOCHEMICA ET CYTOCHEMICA (2012)
Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for In Vivo Somatostatin Receptor Targeting
Meike Koerner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
Shinichi Yachida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Neuroendocrine tumor disease: an evolving landscape
Andrea Frilling et al.
ENDOCRINE-RELATED CANCER (2012)
Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms
Guenter Kloeppel
ENDOCRINE-RELATED CANCER (2011)
Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours
Daniel Kaemmerer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases
L. Righi et al.
ANNALS OF ONCOLOGY (2010)
Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours
V. Zamora et al.
DIGESTIVE AND LIVER DISEASE (2010)
Profiling of Somatostatin Receptor Subtype Expression by Quantitative PCR and Correlation With Clinicopathological Features in Pancreatic Endocrine Tumors
Yoshihito Nakayama et al.
PANCREAS (2010)
Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in Ga-68-DOTATOC PET/CT
Matthias Miederer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Peptide-receptor radionuclide therapy for endocrine tumors
Martijn van Essen et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy
Marco Volante et al.
MODERN PATHOLOGY (2007)
Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors -: A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis
M Papotti et al.
VIRCHOWS ARCHIV (2002)
Share Paper
